Observational studyFrontiers in immunology2026
Anti-PD-1/CTLA-4 bispecific antibody-based combination therapy for cervical cancer: a multicenter study with biomarker analysis.
Jiwei Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.